{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T01:28:40Z","timestamp":1785288520990,"version":"3.55.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.dld.2026.02.018","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:08:47Z","timestamp":1773810527000},"page":"737-746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Practical management of glucagon-like peptide-1 receptor agonists in gastroenterology: a position paper by the Italian Society of Gastroenterology (SIGE)"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2107-2156","authenticated-orcid":false,"given":"Antonio","family":"Facciorusso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8526-837X","authenticated-orcid":false,"given":"Edoardo G","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Tacelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zanetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-2670","authenticated-orcid":false,"given":"Ivo","family":"Boskoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6424-079X","authenticated-orcid":false,"given":"Manuele","family":"Furnari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9518-4751","authenticated-orcid":false,"given":"Grazia","family":"Pennisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0019-8753","authenticated-orcid":false,"given":"Gabriele","family":"Capurso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vitello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-8773","authenticated-orcid":false,"given":"Giovanni","family":"Marasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-1134","authenticated-orcid":false,"given":"Giovanni","family":"Sarnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7417-2655","authenticated-orcid":false,"given":"Luca","family":"Frulloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4992-9289","authenticated-orcid":false,"given":"Marcello","family":"Maida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2026.02.018_bib0001","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.02.018_bib0002","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab065","article-title":"The role of incretins on insulin function and glucose homeostasis","volume":"162","author":"Holst","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.dld.2026.02.018_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.dld.2026.02.018_bib0004","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.02.018_bib0005","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00125-023-05973-w","article-title":"Incretins and cardiovascular disease: to the heart of type 2 diabetes?","volume":"66","author":"Solini","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.dld.2026.02.018_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.1169","article-title":"Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.dld.2026.02.018_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dld.2026.02.018_bib0008","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of Novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dld.2026.02.018_bib0009","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.02.018_bib0010","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1097\/MPA.0000000000002197","article-title":"Glucagon-like peptide 1-based therapies and risk of pancreatic cancer in patients with diabetes and obesity","volume":"51","author":"Krishnan","year":"2022","journal-title":"Pancreas"},{"key":"10.1016\/j.dld.2026.02.018_bib0011","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity","volume":"10","author":"Wang","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.dld.2026.02.018_bib0012","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","article-title":"Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes","volume":"167","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.02.018_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107401","article-title":"Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials","volume":"208","author":"Figlioli","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.dld.2026.02.018_bib0014","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.14309\/ajg.0000000000002519","article-title":"Effects of GLP-1 and other gut hormone receptors on the gastrointestinal tract and implications in clinical practice","volume":"119","author":"Camilleri","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.02.018_bib0015","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4093\/dmj.2025.0242","article-title":"Exploring the side effects of GLP-1 receptor agonist: to ensure its optimal positioning","volume":"49","author":"Kim","year":"2025","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.dld.2026.02.018_bib0016","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions","volume":"9","author":"Jalleh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.02.018_bib0017","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"Newsome","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.02.018_bib0018","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.dld.2026.02.018_bib0019","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.02.018_bib0020","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.02.018_bib0021","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.cgh.2024.01.032","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis","volume":"22","author":"Abushamat","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.02.018_bib0022","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.02.018_bib0023","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.02.018_bib0024","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.02.018_bib0025","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.02.018_bib0026","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.dld.2026.02.018_bib0027","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dld.2026.02.018_bib0028","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.02.018_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2021.07.010","article-title":"Glucagon-like peptide-1 receptor agonists and hepatic decompensation events in patients with cirrhosis and diabetes","volume":"20","author":"Simon","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.02.018_bib0030","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/gutjnl-2024-334591","article-title":"Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies","volume":"74","author":"Celsa","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.dld.2026.02.018_bib0031","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.02.018_bib0032","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis","author":"Souza","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.02.018_bib0033","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.dld.2026.02.018_bib0034","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.02.018_bib0035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/17425255.2023.2252333","article-title":"Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update","volume":"19","author":"Scheen","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.dld.2026.02.018_bib0036","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2024.06.003","article-title":"Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon\/glucagon-like peptide-1 receptor dual agonist, in cirrhosis","volume":"81","author":"Lawitz","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.02.018_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.06.004","article-title":"Glucagon-like peptide-1 receptor agonist use in patients with liver cirrhosis and type 2 diabetes","volume":"22","author":"Yen","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.02.018_bib0038","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/apt.17925","article-title":"Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes","volume":"59","author":"Elsaid","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2026.02.018_bib0039","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.32439","article-title":"Diabetes medications and risk of HCC","volume":"76","author":"Plaz Torres","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.02.018_bib0040","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2174\/15733998113099990068","article-title":"The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: recent findings and new perspectives","volume":"9","author":"Facciorusso","year":"2013","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.dld.2026.02.018_bib0041","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","article-title":"Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease","volume":"78","author":"\u00c5berg","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.02.018_bib0042","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70000","article-title":"Effects of glucagon-like PEPTIDE-1 receptor agonists on incidence of hepatocellular carcinoma and liver decompensation in patients with diabetes: a systematic review and META-analysis","volume":"55","author":"Pasta","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.dld.2026.02.018_bib0043","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/jgh.16752","article-title":"Influence of glucagon-like peptide-1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta-analysis","volume":"40","author":"Passos","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.02.018_bib0044","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12902-024-01775-2","article-title":"Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis","volume":"24","author":"Shabil","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.dld.2026.02.018_bib0045","first-page":"12","article-title":"Statin use decreases the incidence of hepatocellular carcinoma: an updated meta-analysis","author":"Facciorusso","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dld.2026.02.018_bib0046","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13870","article-title":"The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma","volume":"53","author":"Lai","year":"2023","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.dld.2026.02.018_bib0047","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/apt.17371","article-title":"Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin","volume":"57","author":"Zeng","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2026.02.018_bib0048","article-title":"Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis","volume":"57","author":"Wang","year":"2025","journal-title":"Ann Med"},{"key":"10.1016\/j.dld.2026.02.018_bib0049","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1097\/HEP.0000000000000712","article-title":"Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: a Scandinavian cohort study","volume":"79","author":"Engstr\u00f6m","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.02.018_bib0050","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(24)03985-4","article-title":"Association of glucagon-like peptide-1 agonists with cirrhosis and hepatocellular cancer in metabolic dysfunction associated steatotic liver disease (MASLD)","volume":"166","author":"Kanwal","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.02.018_bib0051","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/joim.13751","article-title":"Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: A nationwide cohort study using target trial emulation framework","volume":"295","author":"Yang","year":"2024","journal-title":"J Intern Med"},{"key":"10.1016\/j.dld.2026.02.018_bib0052","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1007\/s11357-024-01494-5","article-title":"Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types","volume":"47","author":"Ungvari","year":"2025","journal-title":"Geroscience"},{"key":"10.1016\/j.dld.2026.02.018_bib0053","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13578-024-01214-8","article-title":"Association of glucose-lowering drug target and risk of gastrointestinal cancer: a mendelian randomization study","volume":"14","author":"Yang","year":"2024","journal-title":"Cell Biosci"},{"key":"10.1016\/j.dld.2026.02.018_bib0054","first-page":"17","article-title":"Differential Effects of GLP-1 receptor agonists on cancer risk in obesity: a nationwide analysis of 1.1 million patients","author":"Levy","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dld.2026.02.018_bib0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/07435800.2021.1955255","article-title":"Differential risk of cancer associated with glucagon-like peptide-1 receptor agonists: analysis of real-world databases","volume":"47","author":"Wang","year":"2022","journal-title":"Endocr Res"},{"key":"10.1016\/j.dld.2026.02.018_bib0056","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.dld.2026.02.018_bib0057","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4093\/dmj.2024.0105","article-title":"Use of glucagon-like peptide-1 receptor agonists does not increase the risk of cancer in patients with type 2 diabetes mellitus","volume":"49","author":"Kim","year":"2025","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.dld.2026.02.018_bib0058","first-page":"16","article-title":"Risk of esophageal and gastric cancer in patients with type 2 diabetes receiving glucagon-like peptide-1 receptor agonists (GLP-1 RAs): a national analysis","author":"Ayoub","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dld.2026.02.018_bib0059","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70490","article-title":"Association between GLP1 RAs use and risk of colorectal cancer: a systematic review and meta-analysis","volume":"8","author":"Bushi","year":"2025","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.dld.2026.02.018_bib0060","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.2337\/db12-1686","article-title":"Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors","volume":"62","author":"Butler","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.dld.2026.02.018_bib0061","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/j.gastro.2011.05.019","article-title":"GLP-1-based therapies: the dilemma of uncertainty","volume":"141","author":"Spranger","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.02.018_bib0062","article-title":"A diabetic patient complicated with pancreatic cancer after using liraglutide: a case","volume":"11","author":"Wu","year":"2020","journal-title":"Report Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.dld.2026.02.018_bib0063","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11096-023-01556-2","article-title":"Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis","volume":"45","author":"Cao","year":"2023","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.dld.2026.02.018_bib0064","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jnci\/djae260","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data","volume":"117","author":"Wang","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.dld.2026.02.018_bib0065","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50408","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes","volume":"7","author":"Dankner","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.dld.2026.02.018_bib0066","first-page":"16","article-title":"The use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus does not increase the risk of pancreatic cancer: a U.S.-based cohort study","author":"Ayoub","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dld.2026.02.018_bib0067","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2337\/dc16-0836","article-title":"Pancreatic effects of liraglutide or sitagliptin in overweight patients with type 2 diabetes: a 12-week randomized, placebo-controlled trial","volume":"40","author":"Smits","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dld.2026.02.018_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102834","article-title":"Semaglutide and cancer: a systematic review and meta-analysis","volume":"17","author":"Nagendra","year":"2023","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.dld.2026.02.018_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinane.2023.111091","article-title":"Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy","volume":"87","author":"Silveira","year":"2023","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.dld.2026.02.018_bib0070","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/jdi.14005","article-title":"Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy","volume":"14","author":"Kobori","year":"2023","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.dld.2026.02.018_bib0071","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1177\/10600280211055804","article-title":"Impact of glucagon-like peptide-1 receptor agonists (GLP-1RA) on food content during esophagogastroduodenoscopy (EGD)","volume":"56","author":"Stark","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.dld.2026.02.018_bib0072","article-title":"American society of anesthesiologists consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists","author":"Joshi","year":"2023","journal-title":"Am Soc Anesthesiologists (ASA) Task Force Preoperative Fast"},{"key":"10.1016\/j.dld.2026.02.018_bib0073","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.14309\/ajg.0000000000002820","article-title":"Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management","volume":"119","author":"Hiramoto","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.02.018_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2024.07.021","article-title":"Effects of glucagon-like peptide-1 receptor agonists on upper gastrointestinal endoscopy: a meta-analysis","volume":"23","author":"Facciorusso","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.02.018_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.gie.2024.10.011","article-title":"Effects of glucagon-like peptide-1 receptor agonists on endoscopy outcomes: systematic review and meta-analysis","volume":"101","author":"Singh","year":"2025","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.dld.2026.02.018_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.gie.2024.12.019","article-title":"Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis","volume":"101","author":"Baig","year":"2025","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.dld.2026.02.018_bib0077","article-title":"Confounding factors in the association between glucagon-like peptide-1 receptor agonist use and retained gastric contents in asymptomatic patients undergoing upper gastrointestinal endoscopy: a retrospective study","volume":"16","author":"Elimihele","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.dld.2026.02.018_bib0078","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.gie.2024.04.2900","article-title":"Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and nondiabetic patients","volume":"100","author":"Nadeem","year":"2024","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.dld.2026.02.018_bib0079","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.14309\/ajg.0000000000002777","article-title":"Glucagon-like peptide-1 receptor agonists increase solid gastric residue rates on upper endoscopy especially in patients with complicated diabetes: a case-control study","volume":"119","author":"Garza","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.02.018_bib0080","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1007\/s12630-024-02781-7","article-title":"In reply: Comment on: Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study","volume":"71","author":"Wu","year":"2024","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.dld.2026.02.018_bib0081","series-title":"Gastroenterology","article-title":"Increased risk of residual gastric content in patients on glp-1 agonists undergoing esophagogastroduodenoscopy","author":"Meluban","year":"2024"},{"key":"10.1016\/j.dld.2026.02.018_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(24)03207-4","article-title":"Clinical impact of glp-1ra on endoscopy: a retrospective cohort study in endoscopy patients","author":"Karlson","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.02.018_bib0083","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(24)01844-4","article-title":"The impact of semaglutide on retained gastric contents during endoscopy","volume":"166","author":"Gu","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.02.018_bib0084","series-title":"Gastroenterology","article-title":"Glucagon-like-peptide-1 receptor agonists (glp-1ra): impact on outpatient upper endoscopy procedure quality","author":"Peng","year":"2024"},{"key":"10.1016\/j.dld.2026.02.018_bib0085","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.gie.2024.05.012","article-title":"Effects of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility and retained gastric contents during EGD","volume":"100","author":"Chapman","year":"2024","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.dld.2026.02.018_bib0086","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2024.03.015","article-title":"Increased risk of aspiration pneumonia associated with endoscopic procedures among patients with glucagon-like peptide 1 receptor agonist use","volume":"167","author":"Yeo","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.02.018_bib0087","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cgh.2024.04.038","article-title":"Glucagon-like peptide-1 receptor agonists do not increase aspiration during upper endoscopy in patients with diabetes","volume":"23","author":"Barlowe","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.02.018_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111900","article-title":"The impact of glucagon-like peptide-1 receptor agonist on the gastric residue in upper endoscopy","volume":"217","author":"Abu-Freha","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dld.2026.02.018_bib0089","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.36783","article-title":"Food Retention at endoscopy among adults using glucagon-like peptide-1 receptor agonists","volume":"7","author":"Nasser","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.dld.2026.02.018_bib0090","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13185403","article-title":"Real-world impact of GLP-1 receptor agonists on endoscopic patient outcomes in an ambulatory setting: a retrospective study at a large tertiary center","volume":"13","author":"Robalino Gonzaga","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2026.02.018_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinane.2024.111668","article-title":"Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: a retrospective single center observational study","volume":"99","author":"Santos","year":"2024","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.dld.2026.02.018_bib0092","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.cgh.2023.11.002","article-title":"AGA rapid clinical practice update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: communication","volume":"22","author":"Hashash","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.02.018_bib0093","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080340","article-title":"Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study","volume":"387","author":"Alkabbani","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2026.02.018_bib0094","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.gie.2014.01.031","article-title":"Boston Bowel Preparation Scale scores provide a standardized definition of adequate for describing bowel cleanliness","volume":"80","author":"Calderwood","year":"2014","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.dld.2026.02.018_bib0095","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.14309\/ajg.0000000000002564","article-title":"Effect of glucagon-like peptide-1 receptor agonists on bowel preparation for colonoscopy","volume":"119","author":"Yao","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.02.018_bib0096","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1176206","article-title":"Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes","volume":"14","author":"Tong","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dld.2026.02.018_bib0097","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/pdi.2110","article-title":"Evaluation of the effect of GLP-1 agonists on quality of bowel preparation for colonoscopy in patients with diabetes","volume":"34","author":"Sharma","year":"2017","journal-title":"Practical Diabetes"},{"key":"10.1016\/j.dld.2026.02.018_bib0098","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/a-2419-3875","article-title":"Glucagon-like peptide-1 receptor agonists significantly affect the quality of bowel preparation for colonoscopy","volume":"57","author":"Abu-Freha","year":"2025","journal-title":"Endoscopy"},{"key":"10.1016\/j.dld.2026.02.018_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.gie.2024.11.024","article-title":"Quality of bowel preparation for colonoscopy in patients on glucagon-like peptide-1 receptor agonists","volume":"101","author":"Gala","year":"2025","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.dld.2026.02.018_bib0100","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(24)01249-6","article-title":"A retrospective analysis of glucagon-like peptide 1 receptor agonists on bowel preparation efficacy in colonoscopies","volume":"166","author":"Zaher","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.02.018_bib0101","article-title":"GLP-1 receptor agonists and other antihyperglycemic agents unlikely to affect bowel preparation: a retrospective cohort study","author":"Vinall","year":"2024","journal-title":"DDW ePoster Library"},{"key":"10.1016\/j.dld.2026.02.018_bib0102","doi-asserted-by":"crossref","first-page":"AB333","DOI":"10.1016\/j.gie.2024.04.2815","article-title":"GLP-1 receptor antagonists do not significantly affect bowel preparation quality","volume":"99","author":"Ritaccio","year":"2024","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.dld.2026.02.018_bib0103","first-page":"14","article-title":"Gastrointestinal safety assessment of GLP-1 receptor agonists in the US: a real-world adverse events analysis from the FAERS database","author":"Osei","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.dld.2026.02.018_bib0104","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/MPA.0000000000000229","article-title":"LEADER 3\u2013lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial","volume":"43","author":"Steinberg","year":"2014","journal-title":"Pancreas"},{"key":"10.1016\/j.dld.2026.02.018_bib0105","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MOG.0000000000001057","article-title":"Incretin mimetics and acute pancreatitis: enemy or innocent bystander?","volume":"40","author":"Pratley","year":"2024","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.dld.2026.02.018_bib0106","article-title":"Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis","volume":"10","author":"Kanie","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.dld.2026.02.018_bib0107","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.dld.2026.02.018_bib0108","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2026.02.018_bib0109","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5144\/0256-4947.2025.129","article-title":"Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis","volume":"45","author":"Safwan","year":"2025","journal-title":"Ann Saudi Med"},{"key":"10.1016\/j.dld.2026.02.018_bib0110","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1210\/jc.2018-01008","article-title":"New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs","volume":"104","author":"Gether","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.dld.2026.02.018_bib0111","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gutjnl-2015-310572","article-title":"GLP-1 based therapies: clinical implications for gastroenterologists","volume":"65","author":"Smits","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.dld.2026.02.018_bib0112","article-title":"Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis","author":"Chiang","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.02.018_bib0113","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13098-024-01526-2","article-title":"The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study","volume":"16","author":"Gameil","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.dld.2026.02.018_bib0114","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dld.2026.02.018_bib0115","article-title":"Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis","volume":"12","author":"Huang","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.dld.2026.02.018_bib0116","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.dld.2026.02.018_bib0117","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/flgastro-2024-102995","article-title":"Anti-obesity drugs for the gastroenterologist","volume":"16","author":"Sharkey","year":"2025","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.dld.2026.02.018_bib0118","article-title":"GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.dld.2026.02.018_bib0119","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2026.02.018_bib0120","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s11739-025-04117-9","article-title":"GLP-1 and GIP agonists in diabetes and obesity and the rise of dyspepsia","volume":"20","author":"Masulli","year":"2025","journal-title":"Intern Emerg Med"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826002963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826002963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:34:45Z","timestamp":1778859285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865826002963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":120,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1590865826002963"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.02.018","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical management of glucagon-like peptide-1 receptor agonists in gastroenterology: a position paper by the Italian Society of Gastroenterology (SIGE)","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}